Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?

TY - JOUR

T1 - Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?

AU - McCloskey, E. V.

AU - Chotiyarnwong, P.

AU - Harvey, N. C.

AU - Lorentzon, M.

AU - Kanis, J. A.

AU - International Osteoporosis Foundation Epidemiology/Quality of Life Working Group

AU - Prieto-Alhambra, D.

AU - Abrahamsen, B.

AU - Adachi, J. D.

AU - Borgström, F.

AU - Bruyere, O.

AU - Carey, J. J.

AU - Clark, P.

AU - Cooper, C.

AU - Curtis, E. M.

AU - Dennison, E.

AU - Diaz-Curiel, M.

AU - Dimai, H. P.

AU - Grigorie, D.

AU - Hiligsmann, M.

AU - Khashayar, P.

AU - Lewiecki, E. M.

AU - Lips, P.

AU - Lorenc, R. S.

AU - Ortolani, S.

AU - Papaioannou, A.

AU - Silverman, S.

AU - Sosa, M.

AU - Szulc, P.

AU - Ward, K.

AU - Yoshimura, N.

N1 - Funding Information: E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. Funding Information: D.P-A. reports institutional receipt of speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier, all outside of the submitted work. Funding Information: B.A. reports grants and personal fees from UCB, personal fees from Amgen, grants from Novartis, grants and personal fees from Pharma-cosmos, grants and personal fees from Kyowa Kirin, personal fees for Gedeon Richter outside the submitted work. BA also serves on the NovoNordisk Foundation Grants Committee on Endocrinology and Metabolism. Funding Information: E.V.M reports consultant/advisor fees, speaker honoraria and or, research funding from AgNovos, Amgen, Consilient Healthcare, Fresenius Kabi, Gedeon Richter, Internis, Lilly, Novartis, ObsEva, Synexus, and UCB, all outside the submitted work.

PY - 2022/8

Y1 - 2022/8

UR - https://www.scopus.com/pages/publications/85133228403

U2 - 10.1007/s00198-022-06419-6

DO - 10.1007/s00198-022-06419-6

M3 - Editorial

C2 - 35763073

SN - 0937-941X

VL - 33

SP - 1631

EP - 1637

JO - Osteoporosis international

JF - Osteoporosis international

IS - 8

ER -